- Home
- APH vs PFE Comparison
APH vs PFE Comparison
Compare APH & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APH | PFE |
|---|---|---|
| Founded | 1932 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7B | 155.2B |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | APH | PFE |
|---|---|---|
| Price | $138.23 | $26.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $154.00 | $29.29 |
| AVG Volume (30 Days) | 6.7M | ★ 25.5M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | 0.67% | ★ 6.55% |
| EPS Growth | ★ 73.96 | N/A |
| EPS | ★ 0.72 | 0.47 |
| Revenue | N/A | ★ $62,579,000,000.00 |
| Revenue This Year | $37.60 | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | $195.72 | ★ $19.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $79.27 | $21.97 |
| 52 Week High | $167.13 | $28.75 |
Technical Indicators
Market Signals| Indicator | APH | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 41.92 |
| Support Level | $127.40 | $24.99 |
| Resistance Level | $144.03 | $27.74 |
| Average True Range (ATR) | 4.86 | 0.55 |
| MACD | -1.37 | -0.09 |
| Stochastic Oscillator | 5.11 | 16.35 |
Price Performance
Historical ComparisonAbout APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. It holds the second-largest connector market share globally and sells into the automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks end markets. Amphenol is diversified geographically, with operations in 40 countries.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.